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ABSTRACT
Background: The National Health Service England,
Commissioning for Quality and Innovation for
Antimicrobial Resistance (CQUIN AMR) aims to reduce
the total antibiotic consumption and the use of certain
broad-spectrum antibiotics in secondary care.
However, robust baseline antibiotic use data are lacking
for hospitalised children. In this study, we aim to
describe, compare and explain the prescription patterns
of antibiotics within and between paediatric units in the
UK and to provide a baseline for antibiotic prescribing
for future improvement using CQUIN AMR guidance.
Methods: We conducted a cross-sectional study using
a point prevalence survey (PPS) in 61 paediatric units
across the UK. The standardised study protocol from
the Antibiotic Resistance and Prescribing in European
Children (ARPEC) project was used. All inpatients
under 18 years of age present in the participating
hospital on the day of the study were included except
neonates.
Results: A total of 1247 (40.9%) of 3047 children
hospitalised on the day of the PPS were on antibiotics.
The proportion of children receiving antibiotics showed
a wide variation between both district general and
tertiary hospitals, with 36.4% ( 95% CI 33.4% to
39.4%) and 43.0% (95% CI 40.9% to 45.1%) of
children prescribed antibiotics, respectively. About a
quarter of children on antibiotic therapy received either
a medical or surgical prophylaxis with parenteral
administration being the main prescribed route for
antibiotics (>60% of the prescriptions for both types of
hospitals). General paediatrics units were surprisingly
high prescribers of critical broad-spectrum antibiotics,
that is, carbapenems and piperacillin-tazobactam.
Conclusions: We provide a robust baseline for
antibiotic prescribing in hospitalised children in relation
to current national stewardship efforts in the UK.
Repeated PPS with further linkage to resistance data
needs to be part of the antibiotic stewardship strategy
to tackle the issue of suboptimal antibiotic use in
hospitalised children.
INTRODUCTION
The increasing levels of antimicrobial resist-
ance (AMR) are strongly correlated with
inappropriate use of antibiotics.1 2 Recent
UK and international reports have advocated
the critical need to monitor and control
the use of existing antibiotics since the
number of new classes of antibiotics has dra-
matically decreased over the past 40 years.3–5
Antimicrobial stewardship programmes
(ASPs), deﬁned as comprehensive quality
improvement activities for optimising anti-
microbial prescribing and minimising resist-
ance, have been widely adopted in adult care
Strengths and limitations of this study
▪ We used a simple, rigorous, validated and stan-
dardised point prevalence method to provide the
baseline for antimicrobial prescribing in hospita-
lised children to assess current and future
national strategies in the UK.
▪ Data were collected from a large sample of
hospitalised children on antibiotics (n=1247)
including a wide variety of different hospitals
(61 institutions) across the UK, wards and
patient characteristics.
▪ Data were collected at the patient level providing
information on the paediatric antimicrobial
prescribing in secondary care adjusted on the
case mix.
▪ Only volunteer hospitals were including in this
cross-sectional study leading to potential selec-
tion biases and limited temporal relationship
between antimicrobial prescribing and covariates.
▪ No consensus exists for measuring antibiotic
prescribing in children as defined daily doses/
100 inpatients is not a validated measure for this
population.
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settings,6 7 but still remain limited in children’s units.8 9
The heterogeneity in age and weight of children, as well
as the lack of a standardised method to quantify anti-
biotic use in paediatrics, increases the challenge of
determining and benchmarking the appropriateness of
prescribing within or between children institutions,10–12
and children are often excluded from comparative
studies on antibiotic use.13 14
The National Health Service England, Commissioning
for Quality and Innovation for Antimicrobial Resistance
(AMR CQUIN) 2016/2017, aims to reduce by 1% or
more per year the total antibiotic consumption and the
use of certain broad-spectrum antibiotics considered as
critical antibiotics (carbapenems and piperacillin-
tazobactam) in secondary care.15–17 However, robust
baseline antibiotic use data, so far developed for adults,
are lacking for hospitalised children while they are key
to measure the impact of the proposed strategies and to
identify room for improvement. Two international
studies have proposed to describe and compare the use
of antimicrobials in children across Europe and world-
wide using various quality indicators,18 19 but no com-
parable detailed information on antibiotic use in
hospitalised children in the UK is available.
The aim of our study is to describe, compare and
explain the prescription pattern of antibiotics across
paediatric units in the UK collected in a cross-sectional
point prevalence survey (PPS) carried out as part of the
Antibiotic Resistance and Prescribing in European
Children (ARPEC) project.20 21 We also proposed to use
the simple PPS to apply AMR CQUIN quality indicators
to provide a baseline of antibiotic prescribing in chil-
dren to measure the impact of the current and future
national strategies.
METHODS
Study design and settings
Detailed antimicrobial prescribing data were collected
for all inpatients aged under 18 years present in a par-
ticipating hospital’s paediatric and neonatal wards at
08:00 since at least midnight. Data collection included
a wide variety of different hospitals, wards and patient
characteristics to be as representative as possible of
hospitalised children in the UK. Data were collected
on paper forms, anonymously entered, validated and
reported online through the ARPEC-PPS programme.
Information on surgical prophylaxis was captured
for the previous 24 hours. Antimicrobial agents
were analysed in accordance with the Anatomical
Therapeutic Chemical (ATC) Classiﬁcation.22 To facili-
tate the data collection on underlying diagnosis
(deﬁned as a pre-existing comorbidity in addition to
the diagnosis of infection for which patients are pre-
scribed antibiotics) and reason for treatment with
antibiotics, predeﬁned lists of grouped items were
used.23 The full method is described elsewhere by
Versporten et al.21
Data extraction
For this study, we extracted and analysed data from 61
paediatric units in the UK which participated in the
ARPEC-PPS organised in March to April 2011 (feasibility
survey), September to November 2011 (worldwide pilot
ARPEC-PPS)21 and October to December 2012 (full
worldwide ARPEC-PPS).19 All inpatients under 18 years
of age admitted to a paediatric ward were included.
We excluded infants on neonatal units and those on
children’s wards under 28 days of age. We analysed
antibacterials for systemic use (ATC J01).
Data analysis
Descriptive analysis
Demographic data, presence or not of an underlying
chronic condition, current diagnosis, hospital-acquired
infections versus community-acquired infections (CAIs),
therapeutic versus prophylactic prescribing, and anti-
biotic type, dosing and route of administration were
analysed and compared between 44 district general hos-
pitals, which provide secondary care, and 17 tertiary
referral hospitals, which provide tertiary or specialised
care.
Metrics for measuring antibiotic use
We compared two different metrics of antibiotic pre-
scribing within and between hospitals: (1) the propor-
tion of children on antibiotics (prevalence rate) with
95% CIs ; (2) the deﬁned daily doses per 100 inpatients
(DDD/100 inpatients), as recommended in the AMR
CQUIN.17 24 Antibiotic consumption in grams was
converted into DDD using the 2013 release of the ATC
Classiﬁcation.22 The denominator ‘inpatients’ was
deﬁned in this study as the sum of inpatients in the
hospital at 08:00.
Quality indicators for national benchmarking between UK
hospitals
We explored the different inpatient antibiotic prescrib-
ing quality indicators proposed by CQUIN NHS
England for AMR.17
1. The total amount of antibiotics prescribed using
both metrics, the proportion of children receiving
antibiotics and DDD/100 inpatients in different age
bands. A funnel plot was used to graphically compare
antibiotic prescribing between hospitals, to adjust for
different hospital sizes and to identify outliers.25 This
takes account of the variable number of cases by insti-
tution by plotting the proportion of children on anti-
biotics against the sample size for each hospital using
a binomial distribution and 95% CI (∼2 SD). We also
displayed antibiotic prescribing in DDD/100 inpati-
ents for each hospital, as well as the median and IQR
for each age band.
2. The use of the carbapenems and the use of
piperacillin-tazobactam, which are both considered
critically important antibiotics against extended-
spectrum β-lactamase producing Gram-negative
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bacteria.3 The proportions of children on carbape-
nems and piperacillin-tazobactam, as well as the
amount of these drugs prescribed in DDD/100 inpa-
tients, were monitored and compared between insti-
tutions after adjusting for hospital type (district
general hospitals vs tertiary referral hospitals) and
presence of underlying disease.
Statistical analyses
We conducted comparative analyses to determine the
balance between district general hospitals and tertiary
referral hospitals using tests of proportions (eg, χ2 ana-
lysis, Fisher’s exact test) and tests of central tendency
(eg, analysis of variance, sign rank). Mean total daily
doses were compared by an unpaired two-sample t-test.
All p values were based on a two-tailed test with p value
<0.05 for signiﬁcance. Statistical analysis was performed
using STATA V.12 (STATA Corp, College Station, Texas,
USA).
Ethics
The responsible UK Research Ethics Committee was
approached to establish the need for a formal evalu-
ation. Written conﬁrmation was provided that within the
UK framework a fully anonymised PPS constituted sur-
veillance and that formal review by the Research Ethics
Committee was not required.
RESULTS
Patient demographics
A total of 1247 (40.9%) of 3047 surveyed UK paediatric
inpatients were receiving antimicrobials. Overall, 1348
indications were recorded for 1247 inpatients with a
total of 1858 antibiotic prescriptions. The median age of
exposed children was 2 years (IQR=0.083–8). More than
two-thirds of inpatients were recruited from tertiary care
centres, and from general paediatric and paediatric
surgery wards (see online supplementary table).
Age differences by specialty were seen among children
on antibiotics. For general paediatrics, the median age
of exposed children was 2 years (IQR=0.75–6), for
surgery 5 years (IQR=1.25–11), for paediatric intensive
care units (PICU) 0.71 years (IQR=0.08–3), for haema-
tology–oncology–transplant 6 years (IQR=2–11) and for
other medical specialties 3 years (IQR=0.75–9).
Total use of antibiotics
Proportion of children on antibiotics
Table 1 shows that the proportion of children on anti-
biotics and the number of prescribed antibiotics was sig-
niﬁcantly higher in tertiary hospitals (43.0%, 95% CI
40.9% to 45.1%, 40 different prescribed antibiotics)
than in district general hospitals (36.4%, 95% CI 33.4%
to 39.4%, 30 different prescribed antibiotics, p=0.001).
About two-thirds of inpatients in intensive or specialist
care wards (PICU and haematology–oncology–trans-
plant) were prescribed antibiotics in high specialist care
areas compared with about one-third in general paediat-
rics and surgery. Multiple antibiotics were also used
more frequently in children admitted to PICU (77/145,
53.1%, 95% CI 45.0% to 61.2%) and haematology–
oncology–transplant units (63/92; 68.5%, 95% CI 59.0%
to 78.0%) compared with children in paediatric surgery
(93/214; 43.5%, 95% CI 36.8% to 50.1%) and general
paediatrics (199/554, 35.9%, 95% CI 31.9% to 39.9%).
Among all children receiving antibiotics, 60.9% (95%
CI 57.5% to 64.4%) of children had an underlying
disease compared with 39.1% (95% CI 34.7% to 43.4%)
of previously healthy children. Exposed children were
more likely to be younger (69.5% exposed below 7 years
of age compared with 30.5% at 7 years and older).
Of 1348 indications, a diagnosis of lower respiratory,
urinary tract, skin and soft tissue, bone or joint infec-
tion, fever and gastrointestinal infection was recorded in
42.2% (CI 38.1% to 46.3%) compared with 18.2% (CI
13.4% to 23.0%) with a diagnosis of severe infections,
that is, sepsis, catheter-related bloodstream infection
(CRBSI), central nervous system (CNS) infection or
febrile neutropaenia. For exposed children, treatment
for CAIs was almost four times more common (59.1%,
CI 55.7% to 62.5%) than for healthcare-associated infec-
tion (15.7%, CI 10.8% to 20.6%). Finally, about a
quarter of children on antibiotic therapy received either
medical (17.3%) or surgical (6.8%) prophylaxis.
Figure 1 shows the funnel plot of the proportion of
children on antibiotic for each institution. Hospitals
with a proportion outside the funnel plot’s 2 SD control
limits are considered to be potential outliers. Seven of
the 61 institutions were identiﬁed as potential ‘high pre-
scribers’, 2 district general hospitals (21 children on
antibiotics) and 5 tertiary referral hospitals (322 chil-
dren on antibiotics). For the two district general hospi-
tals, all children on antibiotics were from general
paediatric wards, aged under 7 years for 76.2% of them
(mainly aged between 1 and 6), with 52.4% of them
having an underlying disease and 80.1% with a common
bacterial infection (lower respiratory tract infection,
urinary tract infection, skin and soft tissue infection,
joint bone tissue infection). For the ﬁve tertiary hospi-
tals, a high proportion of children on antibiotics
(30.1%) were from haematology/oncology/transplant
units and PICU, with a total of 71.4% of children having
an underlying disease and 22.7% of them presenting
with a severe infection (sepsis/CRBSI/CNS/febrile neu-
tropaenia) while 21.1% were on medical prophylaxis. In
total, 73.9% of the children were aged below 7 years
(35.4%<1 and 38.5% between 1 and 6).
Proportion of prescriptions for parenteral versus oral
administration
Parenteral was the main prescribed route for adminis-
trating antibiotics, with more than 60% of the prescrip-
tions in district general hospitals and tertiary referral
hospitals. Parenteral antibiotics were highly prescribed
in PICU (81.6% of the prescriptions), for previous
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Table 1 Proportion of children prescribed antibiotics in paediatric acute care settings across the UK (years 2011, 2012)
N patients treated with
antibiotic
Proportion of children on antibiotic
per cent (95% CI)
N antibiotic prescriptions (total of
different prescribed antibiotics)
Parenteral administration
n (% of prescriptions)
District general hospitals
(n=958 patients)
349 36.4 (33.4 to 39.4) 479 (30) 291 (60.8)
Tertiary referral hospitals
(n=2089 patients)
898 43.0 (40.9 to 45.1) 1379 (40) 861 (62.4)
General paediatric (n=1477) 554 37.5 (35.0 to 40.0) 791 (37) 467 (59.0)
PICU (n=226) 145 64.2 (57.9 to 70.5) 228 (27) 186 (81.6)
Paediatric surgery (n=597) 214 35.8 (32.0 to 39.6) 321 (29) 223 (69.5)
Haematology–oncology–
transplant (n=144)
92 63.9 (56.1 to 71.7) 156 (24) 77 (49.4)
Others (n=603) 242 40.1 (36.2 to 44.0) 362 (31) 199 (55.0)
Total (n patients=3047) 1247 40.9 (39.2 to 42.6) 1858 (41)
N patients treated with
antibiotic (N=1247)
Proportion among total children on
antibiotics per cent (95% CI)
N antibiotic prescriptions (total
of different prescribed antibiotics)
Parenteral administration
n (% of prescriptions)
No underlying disease 487 39.1 (34.7 to 43.4) 689 (30) 483 (70.1)
Underlying disease 760 60.9 (57.5 to 64.4) 1169 (41) 669 (57.2)
Aged <1 year 347 27.8 (23.1 to 32.6) 500 (29) 337 (67.4)
Aged 1–6 years 520 41.7 (37.5 to 46.0) 734 (31) 413 (56.3)
Aged 7–11 years 174 14.0 (8.8 to 19.1) 259 (32) 159 (61.4)
Aged >12 years 206 16.5 (11.4 to 21.5) 363 (36) 243 (66.9)
N indications for
antibiotics (N=1348)
Proportion per cent (95% CI) N antibiotic prescriptions (total
of different prescribed antibiotics)
Parenteral administration
n (% of prescriptions)
Surgical infection 74 5.5 (0.3 to 10.7) 137 (15) 123 (89.8)
Surgical prophylaxis 92 6.8 (1.7 to 11.9) 123 (17) 95 (77.2)
Medical prophylaxis 233 17.3 (12.4 to 22.16) 285 (29) 25 (8.8)
Sepsis/CRBSI/CNS/febrile
neutropaenia
246 18.2 (13.4 to 23.0) 385 (22) 371 (96.4)
URTI 73 5.4 (0.2 to 10.6) 90 (14) 42 (46.7)
LRTI/UTI/SSTI/joint bone/
fever/GITI
569 42.2 (38.1 to 46.3) 764 (35) 458 (60.0)
Other/unknown 61 4.6 (0.0 to 9.7) 74 (22) 38 (51.4)
Community-acquired
infection
797 59.1 (55.7 to 62.5) 1121 (34) 774 (69.1)
Hospital-acquired infection 211 15.7 (10.8 to 20.6) 298 (28) 240 (80.5)
Other (prophylaxis or
unknown)
340 25.2 (20.6 to 29.8) 439 (34) 138 (31.4)
Total 1348 1858 (41)
CRBSI, catheter-related bloodstream infection; CNS, central nervous system; GITI, gastrointestinal tract infection; LRTI, lower respiratory tract infection; PICU, paediatric intensive care units;
SSTI, skin and soft tissue infection; URTI, upper respiratory tract infection; UTI, urinary tract infection.
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healthy children (70.1% of the prescriptions), for surgi-
cal infections (89.8% of the prescriptions) and for
sepsis, CNS infections and febrile neutropaenia (96.4%
of the prescriptions) (table 1).
Total usage of antibiotics in children in DDD/100 inpatients
Table 2 illustrates the total usage of antibiotics in DDD/
100 inpatients for each age category per type of hospital
and specialty. The total amount of antibiotics used is
slightly higher in tertiary hospitals than in district
general hospitals (37.8 vs 30.7 DDD/100 inpatients),
except for children aged 1–6 years. The use of antibio-
tics is about twice as common in haematology–oncol-
ogy–transplant units compared with other specialties,
especially for patients aged above 12 years. For patients
aged below 1 year, the use of antibiotics is substantially
higher in PICU compared with other specialties.
The total prescribed antibiotics in DDD/100 inpati-
ents per age band is shown in ﬁgure 2. A wide range of
antibiotic use is observed among the 61 centres for
patients aged between 12 and 18 years, whereas the
three other groups show greater homogeneity between
institutions in antibiotic usage. The total prescribed anti-
biotics are harmonised between district general hospitals
and tertiary referral hospitals across the four age groups.
Carbapenems and piperacillin-tazobactam
Table 3 shows that among children receiving at least one
antibiotic, the proportion of children on carbapenems
was signiﬁcantly higher in tertiary hospitals than in dis-
trict general hospitals (respectively, n=54, 6.0% vs n=7,
2.0%, p=0.003). The same results were observed for the
total amount of DDD/100 inpatients. Less than half of
the children on carbapenems had at least one under-
lying disease recorded for district general hospitals,
while more than 9 out of 10 had an underlying disease
for tertiary hospitals. In district general hospitals, the
general paediatric wards were the main prescribers of
carbapenems as an empirical treatment, whereas in ter-
tiary hospitals about 43% of the prescriptions were tar-
geted and PICU were the main prescribers.
The amount of piperacillin-tazobactam in DDD/100
inpatients was also surprisingly twofold higher in district
general hospitals than in tertiary hospitals. However, the
proportion of children on piperacillin-tazobactam
among all the children on antibiotics was much higher
in tertiary hospitals. In district general hospitals, most of
the patients were prescribed piperacillin-tazobactam in
paediatric general wards as an empirical treatment when
they had at least one underlying disease, whereas in ter-
tiary hospitals piperacillin-tazobactam was prescribed in
haematology–oncology–transplant wards in the presence
of an underlying disease.
DISCUSSION
We describe a unique inpatient antibiotic prescribing
data set from 61 paediatric units across the UK. Our
results identiﬁed areas of potential improvement for
appropriate prescribing at the patient level adjusting for
risk factors (age, underlying diseases, infections, special-
ties), using the paediatric point prevalence method
developed by the ARPEC project. Our results provide
the baseline for future benchmarking to monitor
national strategies for optimal antimicrobial prescribing
in children, particularly the CQUIN NHS England
scheme 2015/2016 for AMR.
A total of 1247 out of 3047 surveyed admitted children
were on antibiotics in this study. The proportion of chil-
dren receiving antibiotics showed a wide variation
Figure 1 Funnel plot comparing hospital prescribing in the
UK using proportion of children on antibiotics.
Table 2 Total usage of antibiotics in DDD/100 inpatients in paediatric acute care settings across the UK, year 2011–2012
DDD/100 inpatients
Aged <1 year Aged 1–6 years Aged 7–11 years Aged >12 years
District general hospitals, n=958 3.2 12.3 6.0 9.2
Tertiary referral hospitals, n=2089 4.0 10.5 7.1 16.2
General paediatric, n=1477 3.9 11.9 4.7 12.8
PICU, n=226 7.5 12.7 6.4 10.9
Paediatric surgery, n=597 2.1 9.0 10.7 15.7
Haematology–oncology–transplant, n=144 0.45 14.2 14.0 31.7
Others, n=603 4.3 9.7 6.3 11.9
Total 32.9 64.8 118.3 207.5
DDD, defined daily doses; PICU, paediatric intensive care units.
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between district general hospitals and tertiary referral
hospitals, as well as a wide variation within both groups
of hospitals. The presence of case mix and specialties,
such as haematology–oncology–transplant and PICU,
may be responsible for some of the differences observed
in prescribing. Figure 1 highlighted that a total of 7/61
(11.5%) institutions, mainly the haematology–oncology–
transplant and PICU units of the tertiary hospitals, were
identiﬁed as potential ‘high prescribers’. However,
potential ‘high prescribers’ in general district hospitals
Figure 2 Total prescribed antibiotics (DDD/100 inpatients) per age class and type of hospital across the UK during the point
prevalence survey in 2011–1012. DDD, defined daily doses.
Table 3 Total usage of carbapenems and piperacillin-tazobactam in paediatric acute care settings across the UK, year
2011–2012
Carbapenems Piperacillin-tazobactam
District general
hospitals (349
children on
antibiotics)
Tertiary referral
hospitals (898
children on
antibiotics)
District general
hospitals (349
children on
antibiotics)
Tertiary referral
hospitals (898
children on
antibiotics)
Total DDD/100 inpatients 36.4 56.0 39.7 20.0
Total children, n (%)* 7 (2.0) 54 (6.0) 14 (4) 68 (7.6)
General paediatric, n children (%)† 6 (85.7) 14 (25.9) 11 (78.6) 9 (13.2)
PICU, n children (%) 1 (14.3) 17 (31.5) 0 12 (17.6)
Paediatric surgery, n children (%) 0 6 (11.1) 3 (21.4) 7 (10.3)
Haematology–oncology–transplant,
n children (%)
0 10 (18.5) 0 19 (27.9)
Others, n children (%) 0 7 (13.0) 0 21 (30.9)
Underlying disease vs previously
healthy children, n children (%)†
3 (42.9) 49 (90.7) 12 (85.7) 67 (98.5)
*Per cent among the total number of children on antibiotics per type of hospitals.
†Per cent among the number of children on carbapenems or piperacillin-tazobactam.
DDD, defined daily doses; PICU, paediatric intensive care units.
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were only general paediatric units with less than half of
the patients having an underlying disease.
We also highlighted a proportion of patients on
medical prophylaxis (17.3%) similar to that in other
countries (16.9% in Italy and 14.8% on average world-
wide).19 26 Medical prophylaxis appeared to be one of
the most common indications for antibiotic prescribing
in children. The reason, duration and need for prophy-
laxis should be further assessed for quality improvement
through ASPs across paediatric units in the UK, as it is
in adult settings.27
The total usage of antibiotics in DDD/100 inpatients
per age group showed a higher consumption in haematol-
ogy–oncology–transplant units compared with the other
specialties, except for those aged under 1 year receiving
antibiotics in PICU. Children admitted to haematology–
oncology–transplant units or to PICU were more likely to
receive a combination of antibiotics than general and sur-
gical paediatric patients, which may directly impact on
exposure measured in DDD/1000 inpatients.
Carbapenems and piperacillin-tazobactam were mainly
prescribed empirically, and to children with underlying
conditions in tertiary hospitals. These results are
expected and will serve as a benchmark in future evalua-
tions. However, we did not predict that general paediat-
ric units were high prescribers for these two drugs
in district general and tertiary hospitals. With the
spread of extended-spectrum β-lactamase producing
Enterobacteriaceae in adults28 as well as in paediatrics over
the past decade,29 and the increase of small outbreaks
of multidrug-resistant organisms in UK paediatric hospi-
tals,30 the prescribing pattern for these critical drugs
may change in the future and needs to be better moni-
tored, especially in the general paediatric units for previ-
ously healthy children.
There remains a lack of consensus regarding the
optimal metric to assess paediatric antimicrobial use,
which is an important limitation. The use of DDD/100
inpatients (DDD being deﬁned as the amount of
antibiotic prescribed for a 70 kg average adult weight for
its main indication) proposed by CQUIN AMR is not
a perfect measure, especially in children with a wide
range of weights (from 5 kg in a 3 months old to over
100 kg in obese adolescents). Since DDD is weight-
dependent and dose-dependent,31 we decided to
compare overall drug exposure using DDD/100 inpati-
ents in age bands as proposed by Porta et al.24 Despite
DDD/100 inpatients being advocated by the WHO
Collaborating Centre for Drug Statistics and
Methodology, ‘days of therapy’ could have advantages
over DDD measures, because the impact of variation in
absolute dose is limited for this metric.11 31 However, lon-
gitudinal studies or access to electronic-prescribing
systems for each hospital in the UK would be required to
calculate this, which may not be realistic in the near
future.32 For now, DDD/100 inpatients could be used to
monitor changes within units over time as long as the
case mix remains the same. While we have strongly
promoted this study to include a large number of paedi-
atric centres from a wide variety of different hospitals,
wards and patient characteristics across the UK, only vol-
unteer centres were recruited, with the potential for
selection biases. Finally, the PPS methodology provided
limited evidence on the temporal relationship between
antimicrobial prescribing in children and covariates of
interest.
In conclusion, we provide a robust baseline for anti-
biotic prescribing in hospitalised children in relation to
current national stewardship efforts in the UK. Repeated
PPS33 needs to be part of the paediatric antibiotic stew-
ardship strategy in order to identify prescribing trends
over time, to evaluate the efﬁcacy of ASPs and to tackle
the issue of suboptimal antibiotic use, especially on anti-
biotic dosing.34 International standardised PPS with
further linkage between antibiotic prescribing and resist-
ance will be critical to characterise appropriate use of
antibiotics in hospitalised children globally and to
propose guidance on the management of paediatric
infections taking into account resistance proﬁles.
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